Immunotherapy Advances in Gynecologic Cancers

CME

Immunotherapy Advances in Gynecologic Cancers: Insights From ASCO 2024

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: August 01, 2024

Expiration: January 31, 2025

Kathleen N Moore
Kathleen N Moore, MD, MS

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In a post hoc analysis of the phase III RUBY trial of dostarlimab + carboplatin/paclitaxel vs placebo + carboplatin/paclitaxel in patients with advanced or recurrent endometrial cancer, which type of alteration leading to mismatch repair (MMR) deficiency showed progression-free survival (PFS) and overall survival (OS) benefits with the addition of dostarlimab?